Valoctocogene Roxaparvovec Gene Therapy for Severe Hemophilia A

Highlights of Valoctogene Raxaparvovec

- Valoctocogene Roxaparvovec is an investigational gene therapy treatment for Hemophilia A developed by Biomarin

- FDA issued the complete response letter requesting two years of durability data from the phase 3 study

- EMA: Biomarin withdrew MMA application marketing authorization

- Biomarin is awaiting one-year of Phase 3data for EMA resubmission and two years of Phase 3 data for FDA submission

- If approved, it will become first-in-class gene therapy for the treatment of Severe Hemophilia A

For Details Visit

Valoctocogene Roxaparvovec Gene Therapy  for Severe Hemophilia A